Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell INSM and other ETFs, options, and stocks.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
912
Employees912
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
912
Employees912

INSM Key Statistics

Market cap
10.00B
Market cap10.00B
Price-Earnings ratio
-11.84
Price-Earnings ratio-11.84
Dividend yield
Dividend yield
Average volume
3.31M
Average volume3.31M
High today
$66.96
High today$66.96
Low today
$61.52
Low today$61.52
Open price
$64.50
Open price$64.50
Volume
1.99M
Volume1.99M
52 Week high
$70.65
52 Week high$70.65
52 Week low
$19.74
52 Week low$19.74

INSM News

Yahoo Finance 23h
More endpoints met in Insmed's Phase III brensocatib trial - Yahoo Finance

US-based Insmed has shared more data from the Phase III ASPEN trial, showing that brensocatib also reduced the decline in lung function in bronchiectasis patien...

More endpoints met in Insmed's Phase III brensocatib trial - Yahoo Finance
Simply Wall St 1d
Despite currently being unprofitable, Insmed has delivered a 211% return to shareholders over 1 year - Simply Wall St

Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a lot more than 100%. For example, the Insmed...

Despite currently being unprofitable, Insmed has delivered a 211% return to shareholders over 1 year - Simply Wall St
TipRanks 1d
Insmed Reveals Promising Brensocatib Study Results - TipRanks.com - TipRanks

Insmed (INSM) has issued an update. Insmed Incorporated has announced new results from its ASPEN study, which evaluates the effectiveness and safety of the dru...

Analyst ratings

100%

of 17 ratings
Buy
100%
Hold
0%
Sell
0%

More INSM News

Yahoo Finance 2d
Pharma companies shape competitive pipeline for bronchiectasis - Yahoo Finance

The field of bronchiectasis had been previously unexplored, but recent studies have shed light on the mechanisms behind the disease pathophysiology. This has le...

Pharma companies shape competitive pipeline for bronchiectasis - Yahoo Finance
TipRanks 3d
Insmed put volume heavy and directionally bearish - TipRanks.com - TipRanks

Bearish flow noted in Insmed with 4,202 puts trading, or 1.7x expected. Most active are Dec-24 20 puts and Jul-24 75 calls, with total volume in those strikes n...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.